[
    {
        "A_B_Relationship": {
            "Relationship": "Breast Cancer - Capivasertib",
            "Result": [
                "Score: +2 \u2013 Reasoning:  \nAcross all five provided abstracts (PMIDs: 633978, 726741, 817922, 346995, and 369728), treatment with capivasertib failed to show a statistically significant improvement in progression-free survival (PFS), overall survival (OS), or objective response rate (ORR) compared to control arms. Specifically:\n\n\u2022 PMID: 633978 and PMID: 817922 both reported no significant difference in PFS and no OS benefit when capivasertib was combined with paclitaxel.  \n\u2022 PMID: 726741 reported no significant improvement in PFS or OS when capivasertib was combined with fulvestrant.  \n\u2022 PMID: 346995 and PMID: 369728 similarly observed no statistically meaningful improvement in PFS or OS with the addition of capivasertib to paclitaxel.  \n\nIn all five texts, the lack of meaningful improvement in standard clinical outcomes aligns with the hypothesis that capivasertib does not significantly alter breast cancer patient outcomes. Hence, the evidence consistently supports the proposed hypothesis."
            ],
            "Prompt": "Biomedical Abstracts for Analysis:\nPMID: 633978. **Title:** A Phase III Randomized Controlled Trial of Capivasertib in Combination with Paclitaxel for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: Analysis of Efficacy and Safety  \n\n**Objective:**  \nThis phase III trial aimed to evaluate the efficacy and safety of capivasertib, an AKT inhibitor, in combination with paclitaxel compared to paclitaxel alone in patients with advanced hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer. The primary hypothesis was that capivasertib would improve progression-free survival (PFS) in this patient population.  \n\n**Design:**  \nMulticenter, randomized, double-blind, placebo-controlled trial. Patients were stratified by prior endocrine therapy and visceral metastasis status and randomized 1:1 to receive either capivasertib (400 mg twice daily, 4 days on/3 days off) plus paclitaxel (80 mg/m\u00b2 weekly) or placebo plus paclitaxel. Treatment continued until disease progression or unacceptable toxicity.  \n\n**Participants:**  \nEligible patients (n = 450) had metastatic or locally advanced HR+/HER2- breast cancer with progression on \u22651 line of endocrine therapy. Median age was 58 years (range 32\u201379), 65% had visceral metastases, and 72% had prior CDK4/6 inhibitor exposure.  \n\n**Interventions:**  \nPatients received either capivasertib + paclitaxel (n = 225) or placebo + paclitaxel (n = 225) in 28-day cycles.  \n\n**Main Outcome Measures:**  \nPrimary endpoint: PFS by RECIST v1.1. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.  \n\n**Results:**  \nMedian follow-up was 18.2 months. No significant difference in PFS was observed between the capivasertib and placebo arms (median PFS 8.1 vs. 7.9 months; HR 0.95, 95% CI 0.78\u20131.16; p = 0.62). OS data were immature (HR 1.08, 95% CI 0.82\u20131.42; p = 0.58). ORR was similar between groups (38% vs. 35%; p = 0.47). Grade \u22653 adverse events were more frequent with capivasertib (56% vs. 42%), primarily due to hyperglycemia (12% vs. 2%) and diarrhea (8% vs. 3%).  \n\n**Conclusions:**  \nThe addition of capivasertib to paclitaxel did not significantly improve PFS or other efficacy outcomes in patients with advanced HR+/HER2- breast cancer. The combination was associated with increased toxicity, suggesting limited clinical benefit in this setting. Further biomarker-driven studies may be warranted to identify potential responder subsets.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\n---\n\nPMID: 726741. **Title: A Phase III Randomized Controlled Trial of Capivasertib in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: No Significant Improvement in Progression-Free Survival**  \n\n**Introduction:**  \nCapivasertib, a potent AKT inhibitor, has shown preclinical promise in targeting the PI3K/AKT/mTOR pathway, frequently dysregulated in hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer. Despite early-phase trials suggesting antitumor activity, the efficacy of capivasertib in advanced settings remains uncertain. This phase III study evaluated whether adding capivasertib to standard endocrine therapy improves progression-free survival (PFS) in patients with advanced HR+/HER2- breast cancer.  \n\n**Methods:**  \nIn this multicenter, double-blind, placebo-controlled trial, 450 patients with metastatic or locally advanced HR+/HER2- breast cancer were randomized 1:1 to receive either capivasertib (400 mg twice daily, 4 days on/3 days off) plus fulvestrant (500 mg intramuscularly, per standard dosing) or placebo plus fulvestrant. Eligible patients had progressed on prior endocrine therapy. The primary endpoint was investigator-assessed PFS. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Statistical analysis was performed using a stratified log-rank test (two-sided \u03b1 = 0.05), with hazard ratios (HR) and 95% confidence intervals (CI) reported.  \n\n**Results:**  \nMedian follow-up was 18.2 months. The median PFS was 7.4 months (95% CI: 6.1\u20138.5) in the capivasertib arm versus 7.1 months (95% CI: 5.9\u20138.3) in the placebo arm (HR 0.92, 95% CI: 0.75\u20131.13; p = 0.42). No significant difference in OS was observed (HR 1.05, 95% CI: 0.82\u20131.34; p = 0.69). ORR was 22.5% with capivasertib versus 20.8% with placebo (p = 0.64). Grade \u22653 adverse events were more frequent with capivasertib (43% vs. 28%), including hyperglycemia (12% vs. 2%) and diarrhea (9% vs. 1%).  \n\n**Discussion:**  \nThis phase III trial demonstrated no statistically significant improvement in PFS or OS with the addition of capivasertib to fulvestrant in advanced HR+/HER2- breast cancer. While the drug was tolerable, the lack of efficacy suggests limited clinical benefit in this population. Further biomarker-driven studies may identify subsets with AKT pathway dependence who could derive therapeutic advantage.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\n---\n\nPMID: 817922. **Title: A Phase III Randomized Controlled Trial of Capivasertib in Combination with Paclitaxel for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: No Significant Improvement in Progression-Free Survival**  \n\n**Background:** Capivasertib, a potent AKT inhibitor, has shown preclinical activity in hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer. Early-phase trials suggested potential synergy with paclitaxel, warranting further investigation in advanced disease. This phase III study evaluated the efficacy and safety of capivasertib plus paclitaxel versus placebo plus paclitaxel in patients with metastatic or locally advanced HR+/HER2- breast cancer.  \n\n**Methods:** In this double-blind, placebo-controlled trial, 450 patients were randomized 1:1 to receive either capivasertib (400 mg twice daily, 4 days on/3 days off) plus weekly paclitaxel (80 mg/m\u00b2) or placebo plus paclitaxel. The primary endpoint was progression-free survival (PFS) assessed by RECIST v1.1. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Stratification factors included prior CDK4/6 inhibitor use and visceral metastasis. Statistical analysis was performed using a Cox proportional hazards model with a two-sided alpha of 0.05.  \n\n**Results:** Median PFS was 8.1 months (95% CI: 7.2\u20139.0) in the capivasertib arm versus 7.8 months (95% CI: 6.9\u20138.7) in the placebo arm (hazard ratio [HR] 0.93, 95% CI: 0.77\u20131.12; p=0.43). No significant difference in OS was observed (median OS 22.4 vs. 21.7 months; HR 0.98, 95% CI: 0.82\u20131.18; p=0.82). ORR was comparable between groups (38% vs. 35%; p=0.47). Grade \u22653 adverse events were more frequent with capivasertib (56% vs. 42%), primarily due to hyperglycemia (12% vs. 2%) and diarrhea (8% vs. 3%).  \n\n**Conclusion:** The addition of capivasertib to paclitaxel did not significantly improve PFS or OS in patients with advanced HR+/HER2- breast cancer. The combination was associated with increased toxicity, suggesting limited clinical benefit in this population. Further biomarker-driven studies may be needed to identify potential responders.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX  \n\n*Keywords:* Capivasertib, AKT inhibitor, breast cancer, paclitaxel, phase III trial\n\n---\n\nPMID: 346995. **Title: A Phase III Randomized Controlled Trial of Capivasertib in Combination with Paclitaxel for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: Analysis of Efficacy and Safety**  \n\n**Background:**  \nCapivasertib, a potent AKT inhibitor, has shown preclinical promise in targeting the PI3K/AKT/mTOR pathway, frequently dysregulated in hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer. Early-phase trials suggested potential synergy with taxanes, but robust clinical efficacy data are lacking. This phase III study evaluated whether adding capivasertib to paclitaxel improves progression-free survival (PFS) in patients with advanced HR+/HER2- breast cancer.  \n\n**Methods:**  \nIn this multicenter, double-blind, placebo-controlled trial, 450 patients with metastatic or locally advanced HR+/HER2- breast cancer were randomized 1:1 to receive paclitaxel (80 mg/m\u00b2 weekly) with either capivasertib (400 mg twice daily, 4 days on/3 days off) or placebo. The primary endpoint was PFS by blinded independent central review. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Stratification factors included prior CDK4/6 inhibitor use and visceral metastasis. Statistical analysis was performed using a Cox proportional hazards model with a prespecified significance level of p < 0.05.  \n\n**Results:**  \nMedian follow-up was 18.2 months. The capivasertib-paclitaxel combination did not significantly improve PFS compared to placebo-paclitaxel (median PFS 9.4 vs. 8.7 months; hazard ratio [HR] 0.91, 95% CI 0.75\u20131.11; p = 0.34). No OS benefit was observed (median OS 22.1 vs. 21.8 months; HR 0.97, 95% CI 0.79\u20131.19; p = 0.76). ORR was similar between arms (38.2% vs. 35.6%; p = 0.52). Grade \u22653 adverse events were more frequent with capivasertib (56.3% vs. 42.1%), primarily due to hyperglycemia (12.4% vs. 1.8%) and diarrhea (8.7% vs. 2.2%).  \n\n**Conclusion:**  \nThe addition of capivasertib to paclitaxel did not demonstrate a statistically significant improvement in PFS or OS in patients with advanced HR+/HER2- breast cancer. The combination was associated with increased toxicity, suggesting limited clinical utility in this setting. Further biomarker-driven studies may identify subsets benefiting from AKT inhibition.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX  \n\n*Keywords:* Capivasertib, AKT inhibitor, HR-positive breast cancer, paclitaxel, phase III trial\n\n---\n\nPMID: 369728. **Title:** A Phase III Randomized Controlled Trial of Capivasertib in Combination with Paclitaxel for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: Analysis of Efficacy and Safety  \n\n**Objective:** To evaluate the efficacy and safety of capivasertib, an AKT inhibitor, in combination with paclitaxel compared to paclitaxel alone in patients with advanced hormone receptor-positive (HR+), HER2-negative breast cancer.  \n\n**Design:** Multicenter, randomized, double-blind, placebo-controlled phase III trial. Patients were stratified by prior endocrine therapy and visceral metastasis status.  \n\n**Participants:** A total of 450 women (median age 56 years, range 32\u201378) with metastatic or locally advanced HR+/HER2- breast cancer who had progressed on at least one line of endocrine therapy were enrolled between January 2020 and March 2022.  \n\n**Interventions:** Patients were randomized 1:1 to receive either paclitaxel (80 mg/m\u00b2 days 1, 8, 15) plus capivasertib (400 mg twice daily, days 2\u20135, 9\u201312, 16\u201319) or paclitaxel plus placebo in 28-day cycles until disease progression or unacceptable toxicity.  \n\n**Main Outcome Measures:** Primary endpoint was progression-free survival (PFS) by RECIST v1.1. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.  \n\n**Results:** Median PFS was 8.1 months (95% CI: 7.2\u20139.0) in the capivasertib arm versus 7.9 months (95% CI: 7.0\u20138.8) in the placebo arm (hazard ratio [HR] 0.95, 95% CI: 0.78\u20131.16; p = 0.62). No significant difference in OS was observed (median OS 22.4 vs. 21.8 months; HR 0.98, 95% CI: 0.80\u20131.20; p = 0.84). ORR was 35% (95% CI: 29\u201341%) with capivasertib versus 32% (95% CI: 26\u201338%) with placebo (p = 0.47). Grade \u22653 adverse events were more frequent with capivasertib (58% vs. 42%), primarily due to hyperglycemia (12%) and diarrhea (9%).  \n\n**Conclusions:** The addition of capivasertib to paclitaxel did not significantly improve PFS or OS in patients with advanced HR+/HER2- breast cancer. While tolerable, the combination did not demonstrate clinically meaningful benefit over standard chemotherapy alone. Further biomarker-driven studies may identify subsets responsive to AKT inhibition.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\nAvailable PMIDs for Citation: 633978, 726741, 817922, 346995, 369728\n\nAssessment Task:\nEvaluate the degree of support for the hypothesis, which posits a significant interaction between Breast Cancer and Capivasertib. \nThe texts provided above come from PubMed and each abstract will include only Breast Cancer and Capivasertib. \nThe texts need to be your only source of information for arriving at your classification result. \n\nIMPORTANT: You must only cite PMIDs that are explicitly provided in the abstracts above. Do not reference or cite any external literature or PMIDs not in the list above.\n\nHypothesis:\nTreatment with Capivasertib will have no effect on Breast Cancer patient outcomes.\n\nInstructions:\n1. Review each abstract to understand how Breast Cancer and Capivasertib might be interconnected based on the available information.\n2. Analyze the presence and implications of the term pairing (Breast Cancer + Capivasertib) in the context of the hypothesis.\n3. Synthesize the findings from multiple texts. Consider how the pieces fit together to support or refute the hypothesis: Treatment with Capivasertib will have no effect on Breast Cancer patient outcomes.. Remember, no single text may be conclusive.\n4. Provide a justification for your scoring decision based on the analysis. Explain your reasoning step-by-step in terms understandable to an undergraduate biochemist. Focus on explaining the logical connections and the directionality of relationships.\n5. Cite specific texts from your set of abstracts to support your arguments. Only cite PMIDs from the list above, and clearly reference these citations in your reasoning using the format \"PMID: XXXXX\".\n\nFormat your response as:\nScore: [Number] - Reasoning: [Reasoning]\n\nScoring Guidelines:\n\u2022 **-2:** The hypothesis is **refuted** by consistent evidence indicating that the interaction between Breast Cancer and Capivasertib **contradicts** the proposed outcome.\n\u2022 **-1:** The hypothesis is **likely refuted** based on the evidence. There is moderate indication that the interaction between Breast Cancer and Capivasertib **contradicts** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **0:** The hypothesis is **neither supported nor refuted** by the provided texts. The evidence regarding the interaction between Breast Cancer and Capivasertib is inconclusive, mixed, lacks sufficient detail, or there is a lack of evidence.\n\u2022 **+1:** The hypothesis is **likely supported** by the provided texts. The evidence suggests that the interaction between Breast Cancer and Capivasertib may **align with** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **+2:** The hypothesis is **supported** by consistent evidence indicating that the interaction between Breast Cancer and Capivasertib **aligns with** the proposed outcome, with no significant contradictory evidence.",
            "URLS": {
                "AB": [
                    "https://pubmed.ncbi.nlm.nih.gov/633978/",
                    "https://pubmed.ncbi.nlm.nih.gov/726741/",
                    "https://pubmed.ncbi.nlm.nih.gov/817922/",
                    "https://pubmed.ncbi.nlm.nih.gov/346995/",
                    "https://pubmed.ncbi.nlm.nih.gov/369728/"
                ]
            }
        },
        "num_abstracts_fetched": 771
    }
]